Frontline Pembrolizumab or Methotrexate in Elderly, Frail, or Cisplatin-Ineligible Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck: Results of the Randomized Phase 2 Study ELDORANDO (AIO-KHT-0115)
ELDORANDO failed to demonstrate benefit of PEM over MTX regarding 1YOS, ORR, PFS, or OS. The optimal treatment strategy for fragile patients remains to be determined.
Authors
- Viktor Grünwald (ORCID: https://orcid.org/0000-0003-2083-7687)
- Marina Schaaf
- Ingeborg Tinhofer (ORCID: https://orcid.org/0000-0002-0512-549X)
- A.J. Dietz (ORCID: https://orcid.org/0000-0002-5733-7136)
- Stephan Hackenberg (ORCID: https://orcid.org/0000-0001-6995-1849)
- Marlen Haderlein (ORCID: https://orcid.org/0000-0002-7986-2169)
- Ullrich Graeven (ORCID: https://orcid.org/0000-0001-6082-7710)
- D Hahn
- Konrad Klinghammer (ORCID: https://orcid.org/0000-0001-6425-4833)
- Stefan Kasper
- the Interdisciplinary Working Group Head and Neck Cancer of the German Cancer Society (IAG-KHT)
- Disorn Sookthai
- Daniel Pink
- Philipp Ivanyi
Institutions
- Universitätsmedizin Greifswald (DE)
- Medizinische Hochschule Hannover (DE)
- Humboldt-Universität zu Berlin (DE)
- Universitätsklinikum Erlangen (DE)
- Stuttgart Observatory (DE)
- West Cancer Center (US)
- Kliniken Maria Hilf (DE)
- Essen University Hospital (DE)
- Institute of Clinical Cancer Research (DE)
- University Hospital Leipzig (DE)
- Universitätsklinikum Würzburg (DE)
- Klinikum Stuttgart (DE)
- West German Heart and Vascular Center Essen (DE)
Publication Details
- Journal
- Oncology Research and Treatment
- Published
- 2025-12-22
- DOI
- https://doi.org/10.1159/000549947
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00